Cutaneous squamous cell carcinoma: Estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012

Karia, Pritesh S.; Han, Jiali; Schmults, Chrysalyne D.

doi:10.1016/j.jaad.2012.11.037

Cited by 684 publications

(642 citation statements)

References 30 publications

Supporting

Mentioning

596

Contrasting

Unclassified

Order By: Relevance

“…This is partly due to underreporting of minor cases treated in primary care but also due to a high frequency of recurrence when only the primary tumour is recorded -an estimated 30% of cSCC cases go unrecorded (CRUK 2014). In the US approximately 700,000 new cases of cSCC are diagnosed annually but as cSCC has been excluded from national cancer registries there is no precise data concerning incidence, metastases and related mortality (Karia, Han et al 2013). …”

Section: Csccmentioning

confidence: 99%

Tumour–stroma crosstalk in the development of squamous cell carcinoma

Lim

South

2014

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

Section: Csccmentioning

confidence: 99%

Tumour–stroma crosstalk in the development of squamous cell carcinoma

Lim

South

2014

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

“…4,56 The mortality rate for patients diagnosed with a primary skin SCC metastasis is estimated to be approximately 75%. 53,57,84 Similar to BCC, loco-regional therapies, including topical treatments (e.g., 5-FU [fluorouracil]), electrodessication and curettage, and surgery are highly effective in the majority of patients with localized SCC. However, systemic therapy may be required for metastatic SCC, with platinum-based chemotherapeutics and the EGFR (epidermal growth factor receptor) inhibitor cetuximab showing positive results in isolated case reports and a few small case series.…”

Section: Squamous Cell Carcinomamentioning

confidence: 99%

A systematic review of clinical outcomes for patients diagnosed with skin cancer spinal metastases

Goodwin

Sankey

Liu

et al. 2016

SPI

View full text Add to dashboard Cite

OBJECT Surgical procedures and/or adjuvant therapies are effective modalities for the treatment of symptomatic spinal metastases. However, clinical results specific to the skin cancer spinal metastasis cohort are generally lacking. The purpose of this study was to systematically review the literature for treatments, clinical outcomes, and survival following the diagnosis of a skin cancer spinal metastasis and evaluate prognostic factors in the context of spinal skin cancer metastases stratified by tumor subtype. METHODS The authors performed a literature review using PubMed, Embase, CINAHL, and Web of Science to identify articles since 1950 that reported survival, clinical outcomes, and/or prognostic factors for the skin cancer patient population with spinal metastases. The methodological quality of reviews was assessed using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) tool. RESULTS Sixty-five studies met the preset criteria and were included in the analysis. Of these studies, a total of 25, 40, 25, and 12 studies included patients who underwent some form of surgery, radiotherapy, chemotherapy, or observation alone, respectively. Sixty-three of the 65 included studies were retrospective in nature (Class of Evidence [CoE] IV), and the 2 prospective studies were CoE II. Based on the studies analyzed, the median overall survival for a patient with a spinal metastasis from a primary skin malignancy is 4.0 months; survival by tumor subtype is 12.5 months for patients with basal cell carcinoma (BCC), 4.0 months for those with melanoma, 4.0 months for those with squamous cell carcinoma, 3.0 months for those with pilomatrix carcinoma, and 1.5 months for those with Merkel cell carcinoma (p < 0.0001). The overall percentage of known continued disease progression after spine metastasis diagnosis was 40.1% (n = 244/608, range 25.0%–88.9%), the rate of known recurrence of the primary skin cancer lesion was 3.5% (n = 21/608, range 0.2%–100.0%), and the rate of known spine metastasis recurrence despite treatment for all skin malignancies was 2.8% (n = 17/608, range 0.0%–33.3%). Age greater than 65 years, sacral spinal involvement, presence of a neurological deficit, and nonambulatory status were associated with decreased survival in patients diagnosed with a primary skin cancer spinal metastasis. All other clinical or prognostic parameters were of low or insufficient strength. CONCLUSIONS Patients diagnosed with a primary skin cancer metastasis to the spine have poor overall survival with the exception of those with BCC. The median duration of survival for patients who received surgical intervention alone, medical management (chemotherapy and/or radiation) alone, or the combination of therapies was similar across interventions. Age, spinal region, and neurological status may be associated with poor survival following surgery.

show abstract

“…Skin cancer is one of the most common types of cancer worldwide and squamous cell carcinoma (SCC) is the second most common form of skin cancer after basal cell carcinoma (BCC) (1)(2)(3). Treatments used for SCC include surgical excision, topical and systemic chemotherapy (4).…”

Section: Introductionmentioning

confidence: 99%

Anti-Proliferative Effects of Piroxicam and Nimesulide on A431 Human Squamous Carcinoma Cell Line

2017

View full text Add to dashboard Cite

Background: Skin cancer is one of the most common types of cancer worldwide and non-steroidal anti-inflammatory drugs (NSAIDs) have been proposed for prevention and treatment of a variety of cancers. Objectives: In this study we aimed to evaluate the cytotoxic effects of piroxicam (a non-selective cyclooxygenase (COX) inhibitor) and nimesulide (a highly selective COX-2 inhibitor) on A431 human squamous carcinoma cell line. Methods: Squamous carcinoma cell line (A431) was cultured in RPMI medium containing 10% FBS and penicillin-streptomycin at

show abstract

Cutaneous squamous cell carcinoma: Estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012

Cited by 684 publications

References 30 publications

Tumour–stroma crosstalk in the development of squamous cell carcinoma

Tumour–stroma crosstalk in the development of squamous cell carcinoma

A systematic review of clinical outcomes for patients diagnosed with skin cancer spinal metastases

Anti-Proliferative Effects of Piroxicam and Nimesulide on A431 Human Squamous Carcinoma Cell Line

Contact Info

Product

Resources

About